お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にジペプチジルペプチダーゼ-4（DPP-4）阻害剤市場を分類しています。
本レポートでは世界のジペプチジルペプチダーゼ-4（DPP-4）阻害剤市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Merck、Novartis、AstraZeneca、Eli Lilly、Hengrui、Takeda Pharmaceutical、Furiex、Beacon Pharma、Kelun Pharmaceutical、Haisco Pharmaceutical、Easton Biopharmaceuticals

レポートはジペプチジルペプチダーゼ-4（DPP-4）阻害剤の主要生産者を調査し、主要地域や国の消費状況も提供します。ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Sitagliptin
    Saxagliptin
    Vildagliptin
    Linagliptin
    Alogliptin
    Other

用途別の市場セグメント：
    Hospital
    Clinic
    Others

本レポートの詳細内容
本レポートは、世界のジペプチジルペプチダーゼ-4（DPP-4）阻害剤市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてジペプチジルペプチダーゼ-4（DPP-4）阻害剤市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）のジペプチジルペプチダーゼ-4（DPP-4）阻害剤生産量、成長率、市場シェアを調査している。

二. 消費面では、ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーのジペプチジルペプチダーゼ-4（DPP-4）阻害剤売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界のジペプチジルペプチダーゼ-4（DPP-4）阻害剤市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本ジペプチジルペプチダーゼ-4（DPP-4）阻害剤のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：ジペプチジルペプチダーゼ-4（DPP-4）阻害剤のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおけるジペプチジルペプチダーゼ-4（DPP-4）阻害剤の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章ジペプチジルペプチダーゼ-4（DPP-4）阻害剤メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の主要メーカーの概要を提供し、製品の説明と仕様、ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

The global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors market is projected to grow from US$ 308 million in 2025 to US$ 442 million by 2031, at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period.
Dipeptidyl-Peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic drugs used for the treatment of type 2 diabetes. They work by inhibiting the DPP-4 enzyme, which breaks down incretin hormones such as GLP-1, thereby enhancing insulin secretion and reducing glucagon levels in response to meals. This mechanism helps improve blood glucose control without causing significant hypoglycemia. DPP-4 inhibitors are well-tolerated, weight-neutral, and often used in combination with other antidiabetic agents for better glycemic management.
The US & Canada market for Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global key manufacturers of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors include Merck, Novartis, AstraZeneca, Eli Lilly, Hengrui, Takeda Pharmaceutical, Furiex, Beacon Pharma, Kelun Pharmaceutical, Haisco Pharmaceutical, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
In terms of consumption side, this report focuses on the sales of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors by region (region level and country level), by company, by Type and by Application. from 2020 to 2025 and forecast to 2031.
This report presents an overview of global market for Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2020 - 2025, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way. 
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck, Novartis, AstraZeneca, Eli Lilly, Hengrui, Takeda Pharmaceutical, Furiex, Beacon Pharma, Kelun Pharmaceutical, Haisco Pharmaceutical, etc.

Market Segmentation
By Company
    Merck
    Novartis
    AstraZeneca
    Eli Lilly
    Hengrui
    Takeda Pharmaceutical
    Furiex
    Beacon Pharma
    Kelun Pharmaceutical
    Haisco Pharmaceutical
    Easton Biopharmaceuticals

Segment by Type
    Sitagliptin
    Saxagliptin
    Vildagliptin
    Linagliptin
    Alogliptin
    Other

Segment by Application
    Hospital
    Clinic
    Others

Production by Region
    North America
    Europe
    China
    Japan

Sales by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Major Manufacturers of Sitagliptin
 Table 3. Major Manufacturers of Saxagliptin
 Table 4. Major Manufacturers of Vildagliptin
 Table 5. Major Manufacturers of Linagliptin
 Table 6. Major Manufacturers of Alogliptin
 Table 7. Major Manufacturers of Other
 Table 8. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 9. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 10. Global Revenue by Region (2020-2025) & (US$ Million)
 Table 11. Global Revenue Market Share by Region (2020-2031)
 Table 12. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 13. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales by Region (2020-2031) & (K Units)
 Table 14. Global Sales Market Share by Region (2020-2031)
 Table 15. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
 Table 16. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Share by Manufacturers (2020-2025)
 Table 17. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 18. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Manufacturers (2020-2025)
 Table 19. Global Key Players of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, Industry Ranking, 2023 VS 2024 VS 2024
 Table 20. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Price by Manufacturers (2020-2025) & (US$/Unit)
 Table 21. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 22. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors as of 2024)
 Table 23. Global Key Manufacturers of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, Manufacturing Base Distribution and Headquarters
 Table 24. Global Key Manufacturers of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, Product Offered and Application
 Table 25. Global Key Manufacturers of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales by Type (2020-2025) & (K Units)
 Table 28. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales by Type (2026-2031) & (K Units)
 Table 29. Global Sales Share by Type (2020-2031)
 Table 30. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue by Type (2020-2025) & (US$ Million)
 Table 31. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue by Type (2026-2031) & (US$ Million)
 Table 32. Global Revenue Share by Type (2020-2031)
 Table 33. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Price by Type (2020-2025) & (US$/Unit)
 Table 34. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Price Forecast by Type (2026-2031) & (US$/Unit)
 Table 35. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales by Application (2020-2025) & (K Units)
 Table 36. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales by Application (2026-2031) & (K Units)
 Table 37. Global Sales Share by Application (2020-2031)
 Table 38. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue by Application (2020-2025) & (US$ Million)
 Table 39. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue by Application (2026-2031) & (US$ Million)
 Table 40. Global Revenue Share by Application (2020-2031)
 Table 41. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Price by Application (2020-2025) & (US$/Unit)
 Table 42. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Price Forecast by Application (2026-2031) & (US$/Unit)
 Table 43. US & Canada Sales by Type (2020-2031) & (K Units)
 Table 44. US & Canada Revenue by Type (2020-2031) & (US$ Million)
 Table 45. US & Canada Sales by Application (2020-2031) & (K Units)
 Table 46. US & Canada Revenue by Application (2020-2031) & (US$ Million)
 Table 47. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 48. US & Canada Revenue by Country (2020-2031) & (US$ Million)
 Table 49. US & Canada Sales by Country (2020-2031) & (K Units)
 Table 50. Europe Sales by Type (2020-2031) & (K Units)
 Table 51. Europe Revenue by Type (2020-2031) & (US$ Million)
 Table 52. Europe Sales by Application (2020-2031) & (K Units)
 Table 53. Europe Revenue by Application (2020-2031) & (US$ Million)
 Table 54. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 55. Europe Sales by Country (2020-2031) & (K Units)
 Table 56. Europe Revenue by Country (2020-2031) & (US$ Million)
 Table 57. China Sales by Type (2020-2031) & (K Units)
 Table 58. China Revenue by Type (2020-2031) & (US$ Million)
 Table 59. China Sales by Application (2020-2031) & (K Units)
 Table 60. China Revenue by Application (2020-2031) & (US$ Million)
 Table 61. Asia Sales by Type (2020-2031) & (K Units)
 Table 62. Asia Revenue by Type (2020-2031) & (US$ Million)
 Table 63. Asia Sales by Application (2020-2031) & (K Units)
 Table 64. Asia Revenue by Application (2020-2031) & (US$ Million)
 Table 65. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 66. Asia Revenue by Region (2020-2031) & (US$ Million)
 Table 67. Asia Sales by Region (2020-2031) & (K Units)
 Table 68. Middle East, Africa and Latin America Sales by Type (2020-2031) & (K Units)
 Table 69. Middle East, Africa and Latin America Revenue by Type (2020-2031) & (US$ Million)
 Table 70. Middle East, Africa and Latin America Sales by Application (2020-2031) & (K Units)
 Table 71. Middle East, Africa and Latin America Revenue by Application (2020-2031) & (US$ Million)
 Table 72. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 73. Middle East, Africa and Latin America Revenue by Country (2020-2031) & (US$ Million)
 Table 74. Middle East, Africa and Latin America Sales by Country (2020-2031) & (K Units)
 Table 75. Merck Company Information
 Table 76. Merck Description and Major Businesses
 Table 77. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Merck Product Model Numbers, Pictures, Descriptions and Specifications
 Table 79. Merck Recent Developments
 Table 80. Novartis Company Information
 Table 81. Novartis Description and Major Businesses
 Table 82. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novartis Product Model Numbers, Pictures, Descriptions and Specifications
 Table 84. Novartis Recent Developments
 Table 85. AstraZeneca Company Information
 Table 86. AstraZeneca Description and Major Businesses
 Table 87. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. AstraZeneca Product Model Numbers, Pictures, Descriptions and Specifications
 Table 89. AstraZeneca Recent Developments
 Table 90. Eli Lilly Company Information
 Table 91. Eli Lilly Description and Major Businesses
 Table 92. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Eli Lilly Product Model Numbers, Pictures, Descriptions and Specifications
 Table 94. Eli Lilly Recent Developments
 Table 95. Hengrui Company Information
 Table 96. Hengrui Description and Major Businesses
 Table 97. Hengrui Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Hengrui Product Model Numbers, Pictures, Descriptions and Specifications
 Table 99. Hengrui Recent Developments
 Table 100. Takeda Pharmaceutical Company Information
 Table 101. Takeda Pharmaceutical Description and Major Businesses
 Table 102. Takeda Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Takeda Pharmaceutical Product Model Numbers, Pictures, Descriptions and Specifications
 Table 104. Takeda Pharmaceutical Recent Developments
 Table 105. Furiex Company Information
 Table 106. Furiex Description and Major Businesses
 Table 107. Furiex Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Furiex Product Model Numbers, Pictures, Descriptions and Specifications
 Table 109. Furiex Recent Developments
 Table 110. Beacon Pharma Company Information
 Table 111. Beacon Pharma Description and Major Businesses
 Table 112. Beacon Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Beacon Pharma Product Model Numbers, Pictures, Descriptions and Specifications
 Table 114. Beacon Pharma Recent Developments
 Table 115. Kelun Pharmaceutical Company Information
 Table 116. Kelun Pharmaceutical Description and Major Businesses
 Table 117. Kelun Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Kelun Pharmaceutical Product Model Numbers, Pictures, Descriptions and Specifications
 Table 119. Kelun Pharmaceutical Recent Developments
 Table 120. Haisco Pharmaceutical Company Information
 Table 121. Haisco Pharmaceutical Description and Major Businesses
 Table 122. Haisco Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Haisco Pharmaceutical Product Model Numbers, Pictures, Descriptions and Specifications
 Table 124. Haisco Pharmaceutical Recent Developments
 Table 125. Easton Biopharmaceuticals Company Information
 Table 126. Easton Biopharmaceuticals Description and Major Businesses
 Table 127. Easton Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Easton Biopharmaceuticals Product Model Numbers, Pictures, Descriptions and Specifications
 Table 129. Easton Biopharmaceuticals Recent Developments
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Distributors List
 Table 133. Customers List
 Table 134. Market Trends
 Table 135. Market Drivers
 Table 136. Market Challenges
 Table 137. Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources


List of Figures
 Figure 1. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Product Picture
 Figure 2. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Share by Type: 2024 & 2031
 Figure 4. Sitagliptin Product Picture
 Figure 5. Saxagliptin Product Picture
 Figure 6. Vildagliptin Product Picture
 Figure 7. Linagliptin Product Picture
 Figure 8. Alogliptin Product Picture
 Figure 9. Other Product Picture
 Figure 10. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 11. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Clinic
 Figure 14. Others
 Figure 15. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Report Years Considered
 Figure 16. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 18. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue by Region (2020-2031) (US$ Million)
 Figure 19. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Region in Percentage: 2024 Versus 2031
 Figure 20. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Region (2020-2031)
 Figure 21. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales (2020-2031) & (K Units)
 Figure 22. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Figure 23. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Region (2020-2031)
 Figure 24. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales YoY (2020-2031) & (K Units)
 Figure 25. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue YoY (2020-2031) & (US$ Million)
 Figure 26. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales YoY (2020-2031) & (K Units)
 Figure 27. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. China Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales YoY (2020-2031) & (K Units)
 Figure 29. China Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. Asia (excluding China) Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales YoY (2020-2031) & (K Units)
 Figure 31. Asia (excluding China) Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales YoY (2020-2031) & (K Units)
 Figure 33. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue YoY (2020-2031) & (US$ Million)
 Figure 34. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Share by Manufacturers (2024)
 Figure 35. The Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024
 Figure 36. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Share by Manufacturers (2024)
 Figure 37. The Top 5 and 10 Largest Manufacturers of Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors in the World: Market Share by Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue in 2024
 Figure 38. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 39. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2031)
 Figure 40. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Type (2020-2031)
 Figure 41. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Application (2020-2031)
 Figure 42. Global Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 43. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2031)
 Figure 44. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Type (2020-2031)
 Figure 45. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Application (2020-2031)
 Figure 46. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 47. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Share by Country (2020-2031)
 Figure 48. US & Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Share by Country (2020-2031)
 Figure 49. US Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 50. Canada Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 51. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2031)
 Figure 52. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Type (2020-2031)
 Figure 53. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Application (2020-2031)
 Figure 54. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 55. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Share by Country (2020-2031)
 Figure 56. Europe Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Share by Country (2020-2031)
 Figure 57. Germany Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 58. France Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 59. U.K. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 60. Italy Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 61. Russia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 62. China Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2031)
 Figure 63. China Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Type (2020-2031)
 Figure 64. China Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Application (2020-2031)
 Figure 65. China Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 66. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2031)
 Figure 67. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Type (2020-2031)
 Figure 68. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Application (2020-2031)
 Figure 69. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 70. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Share by Region (2020-2031)
 Figure 71. Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Share by Region (2020-2031)
 Figure 72. Japan Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 73. South Korea Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 74. China Taiwan Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 75. Southeast Asia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 76. India Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 77. Australia Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 78. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2031)
 Figure 79. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Type (2020-2031)
 Figure 80. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Market Share by Application (2020-2031)
 Figure 81. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 82. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue Share by Country (2020-2031)
 Figure 83. Middle East, Africa and Latin America Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Sales Share by Country (2020-2031)
 Figure 84. Brazil Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 85. Mexico Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 86. Turkey Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 87. Israel Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 88. GCC Countries Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Revenue (2020-2031) & (US$ Million)
 Figure 89. Value Chain
 Figure 90. Dipeptidyl-Peptidase-4 (DPP-4) Inhibitors Production Process
 Figure 91. Channels of Distribution (Direct Vs Distribution)
 Figure 92. Bottom-up and Top-down Approaches for This Report
 Figure 93. Data Triangulation
 Figure 94. Key Executives Interviewed